Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Rhea-AI Summary

Ernexa Therapeutics (Nasdaq: ERNA) will present in the Virtual Investor Closing Bell Series on Wednesday, February 25, 2026 at 4:00 PM ET. CEO Sanjeev Luther will give a corporate overview and business outlook, take live questions, and a replay will be available two hours after the live event for 90 days.

Investors may register to attend the live webcast and submit questions during the moderated discussion.

News Market Reaction – ERNA

-17.25%

13 alerts

-17.25% Session close to close

-14.1% Trough in 7 hr 59 min

$10.64M Market Cap

0.4x Rel. Volume

In the Feb 20 session, ERNA declined 17.25%, reflecting a significant negative market reaction. Argus tracked a trough of -14.1% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -17.3% in the session following this news. A negative reaction despite a simple in...

Analysis

The stock dropped -17.3% in the session following this news. A negative reaction despite a simple investor-relations announcement would fit a pattern where the stock has sometimes weakened around otherwise constructive updates, such as declines of -25.8% and -1.52% following prior positive news. Filings highlight substantial capital needs and prior dilutive financings, which may keep pressure on sentiment. In that context, even neutral outreach events could coincide with renewed focus on balance sheet and execution risks.

Key Figures

Event date: February 25, 2026 Start time: 4:00 PM ET Replay availability: 90 days

3 metrics

Event date February 25, 2026 Virtual Investor Closing Bell Series participation

Start time 4:00 PM ET Scheduled time of live webcast

Replay availability 90 days Duration webcast replay will remain accessible

Historical Context

5 past events · Latest: Feb 06 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 06	Dilutive offering	Negative	-44.7%	Best-efforts $10.5M equity and warrant offering priced at $0.50 per unit.
Feb 03	Investor segment	Positive	-25.8%	Virtual Investor segment discussing successful Pre-IND meeting and ERNA-101 plans.
Jan 27	Program selection	Positive	-0.8%	Selected among 10 companies for JETRO JEAP to support Japan market entry.
Jan 06	Regulatory update	Positive	+5.0%	Successful FDA Pre-IND meeting outlining path to first-in-human ERNA-101 trial.
Dec 08	Preclinical data	Positive	-1.5%	ASH preclinical data showing strong immune modulation and survival benefits for ERNA-101.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive operational updates have often seen weak or negative price reactions, while dilutive financing drew a sharply negative but directionally aligned move.

Recent Company History

Over the last few months, Ernexa reported multiple milestones around its iMSC programs and financing. A Dec 8, 2025 ASH presentation and a Jan 6, 2026 successful Pre‑IND FDA meeting advanced lead candidate ERNA‑101 toward a first‑in‑human ovarian cancer trial targeted for H2 2026. The company also joined JETRO’s JEAP program and highlighted further FDA alignment in early February. However, a $10.5 million best‑efforts public offering on Feb 6, 2026 triggered a steep selloff, underscoring financing overhang alongside clinical progress.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET

Register here

CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that Sanjeev Luther, President & CEO of Ernexa, will participate in the Virtual Investor Closing Bell Series on Wednesday, February 25, 2026, at 4:00 PM ET.

As part of the segment, Sanjeev Luther, President & CEO of Ernexa, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.

A webcast replay will become available two hours following the live presentation and will be accessible for 90 days.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.

For more information, visit www.ernexatx.com.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ENRA@jtcir.com

FAQ

When will Ernexa Therapeutics (ERNA) present in the Virtual Investor Closing Bell Series?

Ernexa will present on Wednesday, February 25, 2026 at 4:00 PM ET. According to the company, CEO Sanjeev Luther will provide a corporate overview, address the company's business outlook, and take live questions during the moderated webcast.

How can investors watch the ERNA Virtual Investor Closing Bell webcast on February 25, 2026?

Investors can register to view the live webcast and submit questions during the event. According to the company, a replay will be posted two hours after the live presentation and remain accessible for 90 days.

What will CEO Sanjeev Luther discuss during the ERNA webcast on February 25, 2026?

Sanjeev Luther will provide a corporate overview and discuss Ernexa's business outlook during the moderated segment. According to the company, he will also answer as many live investor questions as time allows in the session.

Will Ernexa (ERNA) allow live questions during the February 25, 2026 presentation?

Yes, investors may submit live questions during the moderated presentation. According to the company, management will answer as many questions as possible within the allotted time during the webcast.

How long will the replay of the ERNA Virtual Investor Closing Bell event be available after February 25, 2026?

A replay will be available starting two hours after the live presentation and will remain accessible for 90 days. According to the company, the replay window is intended to give investors convenient access to the session.